1 Day
المصدر:
The Fiscal Times
_1777370220974_847775619.png&w=48&q=75){kind=small}
Moderna stock rises on positive cancer data
Moderna's shares more than doubled after announcing positive initial results from a study of an experimental mRNA-based cancer vaccine, intismeran, developed with Merck. The vaccine, tailored to individual tumor mutations and paired with Merck’s Keytruda, showed patients experienced longer periods without cancer recurrence compared to those receiving only Keytruda in melanoma cases. The companies plan to present full results at an upcoming international medical conference.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading